Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Millipore signs deal with Bayer

Millipore signs deal with Bayer

25th February 2008

Millipore has announced that it has signed a worldwide non-exclusive license agreement with Bayer HealthCare.

Under the agreement, Bayer will use Millipore’s Ubiquitous Chromatin Opening Element technology to produce its biologic drugs.

It is hoped that the deal will ensure that Bayer will be able to manufacture certain recombinant proteins "more efficiently".

Andrew Bulpin, vice president of Millipore’s upstream bioprocessing business unit, said that the companies have developed a "successful relationship".

"This license is another example of how we can help pharmaceutical and biotech companies efficiently manufacture biologic drugs for both commercial use and for use in clinical development," he explained.

Last month, Millipore announced that its revenues for the fourth quarter of last year increased by six per cent.

The company noted that for the full year, its 2007 revenues increased by 22 per cent.

Martin Madaus, chairman and chief executive officer of Millipore, said that the results demonstrated the company’s "solid financial performance".
ADNFCR-1050-ID-18481023-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.